Abstract
A single reference high-performance liquid chromatographic (SR-HPLC) method was developed and validated for the therapeutic drug monitoring (TDM) of phenytoin (PHT) and carbamazepine (CBZ) in plasma from patients. The analytical parameters evaluated were linearity, limit of quantification (LOQ), selectivity, accuracy, and stability according to the US Food and Drug Administration (FDA) guideline. The developed method shows good linearity (r2 > 0.999; LOQ—50 µg/mL), and LOQ values were 1.56 µg/mL for PHT and 0.40 µg/mL for CBZ at 254 nm. For the development of SR-HPLC method, we evaluated to improve the detection wavelength, stirred retention time, and stability for SR, and selected 5-(p-methylphenyl)-5-phenylhydantoin for PHT (relative molar sensitivity, RMS = 0.848) and 10-methoxyiminostilbene for CBZ (RMS = 0.263). The established differential definite quantities of PHT and CBZ in plasma samples were similar using the RMS and absolute calibration methods based on RSD < 5.10%. A preliminary application was performed using chemiluminescent immunoassay and SR-HPLC method, in which the detectable values of the correlation coefficient and the slope of the intercept were PHT: 0.964 and 0.992647, and CBZ: 0.969 and 1.072089, respectively. Based on these results, we propose that the SR-HPLC method with RMS would be offered to the useful and accurate TDM of various medicines in plasma/serum samples.
Graphical abstract
![](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Figa_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs44211-023-00266-z/MediaObjects/44211_2023_266_Fig5_HTML.png)
Similar content being viewed by others
Data availability
On reasonable request, derived data supporting the findings of this study are available from the corresponding author after approval from the Ethical Committee of the Ritsumeikan University.
References
S.H.Y. Wong, J. Pharm. Biomed. Anal. (1989). https://doi.org/10.1016/0731-7085(89)80041-X
A.H. Kumps, J. Pharm. Biomed. Anal. (1982). https://doi.org/10.1007/BF00313405
H.M. Neels, A.C. Sierens, K. Naelaerts, S.L. Scharpé, G.M. Hatfield, W.E. Lambert, Clin. Chem. Lab. Med. (2004). https://doi.org/10.1515/CCLM.2004.245
P.A. Datar, J. Pharm. Anal. (2015). https://doi.org/10.1016/j.jpha.2015.02.005
D.C. Turnell, S.C. Trevor, J.D. Cooper, Ann. Clin. Biochem. (1983). https://doi.org/10.1177/000456328302000106
H. Sayo, H. Hatsumura, M. Hosokawa, J. Chromatogr. (1988). https://doi.org/10.1016/s0378-4347(00)81978-7
G.K. Szabo, R.J. Pylilo, R.J. Perchalski, T.R. Browne, J. Chromatogr. (1990). https://doi.org/10.1016/s0021-9673(01)88952-4
B. Rambeck, T.W. May, M.U. Jürgens, V. Blankenhorn, U. Jürges, E. Korn-Merker, A. Sälke-Kellermann, Ther. Drug Monit. (1994). https://doi.org/10.1097/00007691-199412000-00013
K.M. Patil, S.L. Bodhankar, J. Pharm. Biomed. Anal. (2005). https://doi.org/10.1016/j.jpba.2005.02.045
E. Greiner-Sosanko, D.R. Lower, M.A. Virji, M.D. Krasowski, Biomed. Chromatogr. (2007). https://doi.org/10.1002/bmc.753
M.J. Tutor-Crespo, J. Hermida, J.C. Tutor, J. Clin. Lab. Anal. (2007). https://doi.org/10.1002/jcla.20115
J. Hermida, M.D. Bóveda, F.J. Vadillo, J.C. Tutor, Clin. Biochem. (2002). https://doi.org/10.1016/s0009-9120(02)00299-0
Ó. Guerrero Garduño, D.F. González-Esquivel, C. Escalante-Membrillo, Á. Fernández, I.S. Rojas-Tomé, H. Jung Cook, N. Castro, Biomed. Chromatogr. (2016) https://doi.org/10.1002/bmc.3631
T. Liu, R.R. Kotha, J.W. Jones, J.E. Polli, M.A. Kane, J. Pharm. Biomed. Anal. (2019). https://doi.org/10.1016/j.jpba.2019.112816
S.T. Hassib, H.M.A. Hashem, M.A. Mahrouse, E.A. Mostafa, Biomed. Chromatogr. (2018). https://doi.org/10.1002/bmc.4253
L. Yin, T. Wang, M. Shi, Y. Zhang, X. Zhao, Y. Yang, J. Gu, J. Sep. Sci. (2016). https://doi.org/10.1002/jssc.201501067
M. Takahashi, Y. Nishizaki, N. Sugimoto, K. Sato, K. Inoue, J. Chromatogr. A (2018). https://doi.org/10.1016/j.chroma.2018.04.029
M. Takahashi, Y. Nishizaki, K. Morimoto, N. Sugimoto, K. Sato, K. Inoue, Sep. Sci. Plus 1(2018) https://doi.org/10.1002/sscp.201800081
M. Takahashi, Y. Nishizaki, N. Masumoto, N. Sugimoto, K. Sato, K. Inoue, J. Sci. Food Agric. (2021). https://doi.org/10.1002/jsfa.11013
M. Takahashi, K. Morimoto, Y. Nishizaki, N. Masumoto, N. Sugimoto, K. Sato, K. Inoue, Chem. Pharm. Bull. (2022). https://doi.org/10.1248/cpb.c21-00621
Guidance for Industry, Bionanalytical Method Validation, US Department of Health and Human Services/Food and Drug Administration Centre for Drug Evaluation and Research (CDER)/Centre for Veterinary Medicine (CVM), 2018, May.
H. Passing, Bablok. J. Clin. Chem. Clin. Biochem. (1983). https://doi.org/10.1515/cclm.1983.21.11.709
R.H. Queiroz, C. Bertucci, W.R. Malfará, S.A. Dreossi, A.R. Chaves, D.A. Valério, M.E. Queiroz, J. Pharm. Biomed. Anal. (2008). https://doi.org/10.1016/j.jpba.2008.03.020
M.M. Bhatti, G.D. Hanson, L. Schultz, J. Pharm. Biomed. Anal. (1998). https://doi.org/10.1016/s0731-7085(97)00265-3
The Japanese Pharmacopoeia, Eighteenth Edition, 2.46 Residual Solvents, June 7 (2021) 58–64. https://www.mhlw.go.jp/content/11120000/000943877.pdf
A. Dasgupta, M.A. Reyes, B.G. Davis, A.M. Marlow, M. Johnson, J. Clin. Lab. Anal. (2010). https://doi.org/10.1002/jcla.20400
G.A. McMillin, J.M. Juenke, G. Tso, A. Dasgupta, Am. J. Clin. Pathol. (2010). https://doi.org/10.1309/AJCPFAHVB26VVVTE
G.A. McMillin, J.M. Juenke, M.J. Johnson, A. Dasgupta, J. Clin. Lab. Anal. (2011). https://doi.org/10.1002/jcla.20460
R. Takahashi, K. Imai, S. Sugai, T. Yoshida, M. Nakamura, S. Hamano, F. Iwasaki, Iryo Yakugaku. (2012). https://doi.org/10.5649/jjphcs.38.741
D.A. Svinarov, C.E. Pippenger, Ther. Drug Monit. (1996). https://doi.org/10.1097/00007691-199612000-00006
Acknowledgements
We thank Dr. Miki Takahashi, Dr. Yuzo Nishizaki, Dr. Naoki Sugimoto, and Dr. Kyoko Sato from National Institute of Health Sciences, Japan for their technical assistance and SR advice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this study.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sakaguchi, Y., Arima, R., Maeda, R. et al. Development of a useful single-reference HPLC method for therapeutic drug monitoring of phenytoin and carbamazepine in human plasma. ANAL. SCI. 39, 447–454 (2023). https://doi.org/10.1007/s44211-023-00266-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s44211-023-00266-z